RNA sequencing Introduction (What it is)
RNA sequencing is a laboratory test that reads the RNA (gene messages) made by cells in a sample.
In cancer care, it helps clinicians understand which genes a tumor is actively using.
It is commonly used alongside standard pathology and DNA testing to refine diagnosis and treatment planning.
It may be performed on tumor tissue, bone marrow, or sometimes blood-derived material, depending on the case.
Why RNA sequencing used (Purpose / benefits)
Cancer is not only defined by what a tumor looks like under the microscope, but also by how it behaves at the molecular level. While DNA testing shows potential genetic changes (mutations and rearrangements), RNA sequencing focuses on gene activity—what the cancer cells are actually expressing right now. That “activity map” can add clinically useful context.
In oncology, RNA sequencing is used to help solve problems such as:
- Clarifying diagnosis when pathology is uncertain. Some cancers share similar appearances, especially in small biopsies or rare tumors. RNA patterns can support more precise classification.
- Identifying actionable targets and pathways. Certain therapies are guided by specific biomarkers. RNA sequencing can reveal gene fusions or abnormal expression that may point to targeted treatments, depending on the cancer type and available drugs.
- Detecting gene fusions that may be missed by other methods. Many clinically relevant fusions produce abnormal RNA transcripts; RNA-based methods can sometimes detect these more directly than DNA-only approaches.
- Refining prognosis and risk grouping. In some settings, gene-expression signatures help estimate risk categories or expected behavior. How this is used varies by cancer type and stage.
- Supporting treatment selection and clinical trial matching. Results may help identify eligibility for biomarker-driven trials, especially when standard options are limited.
Importantly, RNA sequencing is typically one piece of a broader diagnostic picture that also includes symptoms, imaging, histology (microscopic examination), staging, and other lab tests.
Indications (When oncology clinicians use it)
Common scenarios where oncology teams may consider RNA sequencing include:
- A new cancer diagnosis where standard pathology does not clearly define the tumor type
- Suspected gene fusion–driven cancers (for example, some sarcomas, certain lung cancers, and selected pediatric tumors)
- Advanced or metastatic cancer when additional biomarker information could affect systemic therapy choices
- Hematologic malignancies (such as leukemias) where RNA-based fusion detection or expression profiling may refine classification
- Tumors of unknown primary, when the site of origin is unclear after initial workup
- Relapsed or refractory disease, where updated molecular profiling may support trial matching
- Situations where DNA sequencing did not find a clear driver alteration, but a transcriptional (RNA) signal might still be present
- Cases discussed in a multidisciplinary tumor board where additional molecular clarification is needed
Contraindications / when it’s NOT ideal
RNA sequencing is not always the best test for every patient or every sample. Situations where it may be less suitable, or where another approach may be preferred, include:
- Insufficient or poor-quality sample. RNA can degrade more easily than DNA, particularly in small biopsies or older stored specimens.
- Low tumor content. If the sample contains very few cancer cells mixed with normal tissue, results may be difficult to interpret.
- When a faster single-gene test is needed. If an urgent treatment decision depends on one biomarker, targeted tests (such as PCR, immunohistochemistry, or FISH) may return results sooner.
- When the key question is a DNA mutation rather than expression. Many therapy decisions rely on DNA variants best captured by DNA sequencing.
- Technical or logistical constraints. Turnaround time, laboratory capacity, insurance coverage, and local workflows vary by clinician and case.
- When established guidelines prioritize other assays first. For some cancers, standard-of-care testing sequences are well defined, and RNA sequencing may be reserved for specific gaps.
How it works (Mechanism / physiology)
RNA sequencing is a diagnostic laboratory method, not a treatment. It does not act on the body directly. Instead, it measures biological information from a collected sample.
At a high level, the process reflects core tumor biology:
- Genes are transcribed into RNA. DNA is the blueprint; RNA is the working copy used to make proteins and regulate cell behavior.
- Cancer changes gene regulation. Tumors often show abnormal RNA patterns: overexpression of growth signals, loss of normal differentiation signals, immune-related signals, or fusion transcripts created by rearranged chromosomes.
- RNA can capture functional consequences. Some DNA changes matter because they alter RNA and protein output. Measuring RNA can sometimes show whether a pathway is “turned on.”
Clinically, RNA sequencing most often supports three pathways:
- Diagnostic classification: Comparing expression patterns or detecting fusion transcripts that define specific tumor entities.
- Predictive biomarker support: Identifying RNA features that may correlate with response to certain therapies (varies by cancer type and stage).
- Research and trial enrollment: Providing deeper molecular context for investigational strategies.
Onset and duration/reversibility: These concepts do not apply in the same way they would for a medication or radiation therapy. Instead, the closest relevant properties are:
- Turnaround time: How long it takes for results to return varies by lab and clinical urgency.
- Temporal variability: RNA expression can change over time and with treatment, so results reflect the tumor state at the time and site of sampling.
RNA sequencing Procedure overview (How it’s applied)
RNA sequencing is best understood as a step within a broader cancer evaluation and treatment planning workflow. A typical high-level pathway looks like this:
- Evaluation/exam: Symptoms, medical history, physical exam, and baseline lab tests guide the initial suspicion.
- Imaging/biopsy/labs: Imaging may locate disease; a biopsy (or bone marrow sampling in some blood cancers) provides tissue for pathology and molecular testing.
- Pathology confirmation: A pathologist evaluates the sample with microscopy and may use immunohistochemistry and other staining methods.
- Staging: Imaging and clinical findings determine cancer stage (extent of disease). Staging systems vary by cancer type.
- Molecular testing selection: The care team chooses tests (DNA sequencing, RNA sequencing, FISH, PCR, etc.) based on the clinical question, tissue availability, and guidelines.
- RNA sequencing in the lab: RNA is extracted from the sample, converted to a readable format, sequenced, and analyzed using bioinformatics to generate a report.
- Treatment planning: Results are integrated with stage, pathology, performance status, and patient goals. Many centers review complex cases in a tumor board.
- Intervention/therapy: Treatment may include surgery, radiation therapy, systemic therapy (chemotherapy, targeted therapy, immunotherapy), or a combination—depending on the diagnosis and stage.
- Response assessment: Imaging, blood tests, and clinical assessment track response and side effects.
- Follow-up/survivorship: Long-term monitoring addresses recurrence risk, late effects, rehabilitation needs, and supportive care.
Types / variations
RNA sequencing is a broad term covering multiple test designs and clinical use cases. Common variations include:
- Whole-transcriptome (RNA-Seq) profiling: Measures a wide range of RNA transcripts across the genome to assess overall gene expression patterns. Often used when a broad view is needed.
- Targeted RNA panels: Focus on a selected set of genes, commonly to detect gene fusions or specific expression markers with a streamlined workflow.
- Fusion-focused assays: Designed specifically to identify fusion transcripts (for example, rearrangements involving ALK, ROS1, RET, NTRK, or others), depending on the panel.
- Bulk RNA sequencing vs single-cell approaches:
- Bulk RNA sequencing measures average expression across all cells in the sample.
- Single-cell methods analyze individual cells and are more common in research than routine clinical care.
- Tissue-based vs blood-based approaches: Most clinical testing is tissue-based. Blood-based RNA methods (such as cell-free RNA approaches) exist but are less standardized in routine oncology and may be used mainly in research or specialized contexts.
- Solid-tumor vs hematologic applications:
- In solid tumors, RNA sequencing is often used for fusion detection and expression profiling that complements DNA findings.
- In hematologic malignancies, it may support classification and fusion detection alongside cytogenetics and flow cytometry.
- Adult vs pediatric oncology: Pediatric cancers more often involve fusion-driven biology in some categories, so RNA-based fusion detection may be particularly relevant in selected pediatric cases, depending on the suspected diagnosis and local practice.
Pros and cons
Pros:
- Can detect gene fusions and abnormal transcripts that directly reflect tumor biology
- Adds functional context (gene activity) beyond DNA changes alone
- May help clarify difficult diagnoses, especially in rare tumors or limited biopsy material
- Can support biomarker-driven treatment planning and clinical trial matching (varies by cancer type and stage)
- Often complements standard pathology, improving confidence in classification when multiple data sources align
- Can reveal pathway activity and tumor microenvironment signals in some reporting frameworks
Cons:
- Requires adequate, well-preserved RNA; degraded samples can limit accuracy or lead to test failure
- Results can be complex and may not always change clinical management
- Turnaround time may be longer than single-marker tests in some settings
- Interpretation depends on bioinformatics pipelines and reference databases; reports can differ between laboratories
- Expression can vary by sampling site and timing (for example, before vs after treatment), complicating comparisons
- Insurance coverage and access can be inconsistent, varying by clinician and case
Aftercare & longevity
Because RNA sequencing is a test rather than a treatment, “aftercare” focuses on what happens after results are reported and how they are used in ongoing care.
What most affects the practical value and “longevity” of results includes:
- Cancer type and stage: Molecular results may be more actionable in some cancers and in advanced disease settings, while early-stage care may rely more on surgery and standard pathology.
- Tumor biology and heterogeneity: Different tumor areas (or primary vs metastasis) can show different expression patterns. This may influence whether repeat sampling is considered later.
- Treatment exposure: Therapies can shift gene expression, so an older result may become less representative over time, especially after multiple treatment lines.
- Integration with other findings: RNA findings are strongest when consistent with histology, imaging, and DNA results. Discordant findings may require additional confirmatory testing.
- Follow-up systems: Timely communication of results, tumor board review, and clear documentation help ensure results are used appropriately.
- Supportive care and comorbidities: Even when a biomarker suggests a potential therapy, overall treatment planning still depends on organ function, symptoms, and concurrent conditions.
- Access to specialized services: Availability of molecular tumor boards, genetics services, and clinical trials can affect whether results lead to additional options.
Alternatives / comparisons
RNA sequencing is one option within molecular diagnostics and is usually complementary rather than a replacement for standard care.
Common alternatives or related approaches include:
- Standard histopathology (microscopy) and immunohistochemistry (IHC): Often the foundation of diagnosis. IHC detects proteins rather than RNA and can be faster and widely available, but may not identify specific gene fusions or broader expression profiles.
- FISH (fluorescence in situ hybridization): A targeted method to detect certain rearrangements. It can be very useful for specific questions but typically evaluates fewer targets at once than many RNA sequencing panels.
- RT-PCR or other targeted PCR assays: Highly focused and sensitive for known transcripts, but limited to predefined targets.
- DNA sequencing (tumor DNA panels or broader sequencing): Better for many mutation types and is commonly paired with RNA sequencing. DNA can suggest a fusion partner or mutation, while RNA can confirm whether it is expressed.
- Cytogenetics and flow cytometry (especially in blood cancers): Provide structural chromosome information and cell-surface marker patterns that remain central to many hematologic diagnoses.
- Gene expression microarrays: An older expression technology used in some settings; RNA sequencing generally offers broader detection and transcript detail, though local availability varies.
- Observation/active surveillance: Not an “alternative test,” but in some clinical scenarios, immediate molecular expansion may not be needed if management is unlikely to change. Decisions vary by cancer type and stage.
- Clinical trials: Trials may require or provide specific molecular testing. Participation depends on eligibility, location, and individual circumstances.
RNA sequencing Common questions (FAQ)
Q: Is RNA sequencing a treatment or a test?
RNA sequencing is a laboratory test performed on a sample (such as tumor tissue or bone marrow). It helps describe gene activity and certain molecular features of cancer. Treatment decisions, if any, are based on the whole clinical picture, not the test alone.
Q: Does RNA sequencing hurt? Will I feel anything?
The sequencing itself does not cause pain because it happens in a laboratory. Any discomfort usually relates to how the sample is collected, such as a biopsy or blood draw. Pain control and sedation choices depend on the procedure type and site.
Q: Will I need anesthesia for RNA sequencing?
Anesthesia is not used for sequencing, but it may be used for the biopsy or procedure that obtains the sample. Some biopsies are done with local anesthetic, while others may use sedation or general anesthesia. The approach varies by clinician and case.
Q: How long does RNA sequencing take to get results?
Turnaround time varies by laboratory method, sample quality, and whether testing is done in-house or sent out. Some targeted assays return sooner than broader profiles. Your care team typically coordinates timing with treatment planning needs.
Q: Are there side effects or safety risks from RNA sequencing?
RNA sequencing does not expose you to radiation or medication side effects. The main risks relate to sample collection (for example, bleeding, infection, or soreness after a biopsy), which depend on the biopsy site and technique. Laboratories also have quality controls to reduce technical errors, but no test is perfect.
Q: What does it mean if RNA sequencing finds a “fusion” or “overexpression”?
A fusion is an abnormal joining of two genes that can drive cancer growth in certain tumor types. Overexpression means a gene is producing more RNA than expected, which may or may not be clinically meaningful. Whether these findings affect treatment options varies by cancer type and stage and often requires correlation with other tests.
Q: If my RNA sequencing report is “negative,” does that mean I don’t have cancer?
No. A negative or non-informative result usually means the test did not detect certain RNA features it was designed to find. Cancer diagnosis typically relies on pathology and clinical evaluation, and RNA sequencing is an add-on tool rather than a standalone rule-out test.
Q: Will RNA sequencing affect my ability to work or do normal activities?
The sequencing does not limit activities, but the biopsy or procedure used to obtain tissue might. Activity limits, if any, depend on the biopsy site and recovery. Many people return to usual routines quickly after minor procedures, but timelines vary.
Q: How much does RNA sequencing cost?
Costs vary widely based on the type of test (targeted vs broad), the laboratory, insurance coverage, and regional billing practices. Some patients have out-of-pocket costs, while others have coverage when the test meets specific criteria. Financial counseling services at cancer centers can often help clarify expected charges.
Q: Can RNA sequencing affect fertility or pregnancy?
RNA sequencing itself does not affect fertility because it is not a therapy. However, the results might be used to guide treatments that could have fertility implications (such as certain chemotherapies or radiation plans). Fertility considerations are highly individual and depend on the treatment strategy rather than the sequencing test.
Q: Will I need RNA sequencing more than once?
Sometimes. Because tumors can change over time and after treatment, repeat testing may be considered in relapsed or metastatic disease or when a new biopsy is performed. Whether repeat RNA sequencing is useful depends on the clinical question, sample availability, and what prior testing has already shown.